Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukaemia

Orlev Levy-Nissenbaum, Orit Sagi-Assif, Pia Raanani, Abraham Avigdor, Isaac Ben-Bassat, Isaac P. Witz*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


In a previous study we used gene expression arrays to identify genes that are more highly expressed by leukemic than by non-leukemic leukocytes from acute myelogenous leukemia patients. One of such genes was Phosphorylates tyrosine serine threonine 2 (PYST2), a dual-specificity Mitogen-activated protein (MAP) kinase (MAPK) phosphatase. In the present study, high levels of PYST2 mRNA were detected by RT-PCR and by Northern blotting in bone marrow (BM) leukocytes and in peripheral blood mononuclear cells from additional eight AML patients. No PYST2 mRNA was detected in nine out of twelve samples of Peripheral blood mononuclear cells (PBMC) from healthy blood bank donors and very low levels were detected by the same techniques in the other three PBMC samples from the healthy donors. Relatively high levels of PYST2 were detected in a variety of myeloid leukemia and other cancer cell lines. In view of the potential role played by PYST2 in MAPK signaling cascades we propose that an over expression of PYST2 in malignant cells may reflect a disrupted or an altered MAPK signaling pathway in malignancy processes.

Original languageEnglish
Pages (from-to)185-192
Number of pages8
JournalCancer Letters
Issue number2
StatePublished - 25 Sep 2003


FundersFunder number
Gabrielle Rich Leukemia Research Foundation
James J. Leibman and Rita S. Leibman Endowment Fund for Cancer Research


    • Acute leukemia
    • Acute myelogenous leukemia
    • Dual-specificity phosphatases (DUSP)
    • Gene expression
    • MAPK
    • PYST2
    • cDNA microarray


    Dive into the research topics of 'Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukaemia'. Together they form a unique fingerprint.

    Cite this